|
|
News Breaks
|
November 9, 2011
|
| 16:35 EDT |  | MAXY |
| theflyonthewall.com: | Maxygen not to awarded contract for development of Maxy-G34 by BARDA | | Maxygen announced that it has been advised by the Biomedical Advanced Research and Development Authority, or BARDA, that Maxygen's proposal for the development of its Maxy-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome, or ARS, will not be considered for a contract award. Maxygen submitted a white paper entitled Development of Maxy-G34 as a Medical Countermeasure for Acute Radiation Syndrome in December 2010 in response to a Broad Agency Announcement. Following review of the white paper, in February BARDA invited Maxygen to prepare a full proposal which the company then submitted in May. BARDA found Maxygen's proposal technically sound and highlighted the novel attributes of Maxy-G34, the comprehensive nature of the development plan, the promising efficacy data in animal models and the safety data in previous studies of Maxy-G34 in breast cancer patients. However, BARDA also noted several weaknesses in the proposal, including dependence on overseas manufacturing, uncertainty regarding intellectual property issues with respect to Maxy-G34 and the company's reliance on consultants and subcontractors. :theflyonthewall.com |
|
|
News For MAXY From The Last 14 Days Check below for free stories on MAXY the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 14, 2012
|
| 09:03 EDT | | MAXY |
|
|
|
|
|
Subscribe for More Information